Recent studies have highlighted the dual immunomodulatory roles of CD300 family members in tumor immunity, with CD300a acting as an inhibitory checkpoint and CD300c serving as an activating receptor that promotes pro-inflammatory responses in myeloid cells (20). Here, CD300C is linked to neoplasm.